Cognitive stimulation therapy in people with intellectual disability and dementia

Feasibility randomised controlled trial of individual Cognitive Stimulation Therapy (iCST) for dementia in people with intellectual disability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18312288

Enrollment

111

Registered

2017-09-12

Start date

2017-12-01

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia in people with an intellectual disability Mental and Behavioural Disorders Dementia

Interventions

Participants are randomly assigned to the intervention or control arm using a web based system called Sealed Envelope. Those in the control arm with receive treatment as usual. Those in the interventi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of mild- moderate intellectual disability 2. Diagnosis of mild- moderate dementia 3. Aged 40 years old or above 4. Suitable verbal communication in English 5. No significant visual or hearing impairment 6. No significant physical illness, physical disability or behavioural problems that would affect participation 7. A willing carer available to deliver the intervention

Exclusion criteria

Exclusion criteria: 1. Severe intellectual disability 2. Late stage dementia 3. Significant hearing or visual impairment 4. Unable to speak English 5. No carer willing to participate in the study

Design outcomes

Primary

Measure	Time frame
Participant’s cognitive functioning will be measured using the CAMCOG-DS at baseline, 11 weeks and 21 weeks.	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 03/08/2018: 1. Participants cognitive functioning is measured using the Modified Memory for Objects test from the Neuropsychological Assessment of Dementia in Intellectual Disabilities Battery at baseline, 11 weeks and 21 weeks, and the Cognitive Scale for Down Syndrome (CS-DS) at baseline, 11 weeks and 21 weeks. 2. Functional ability is measured using ADCS- Activities of Daily Living Inventory (ADCS-ADL) at baseline, 11 weeks and 21 weeks 3. Participant’s health related quality of life is measured using the QOL-AD proxy at baseline, 11 weeks and 21 weeks 4. Caregiver burden is measured using the Care Giving Burden Scale at baseline, 11 weeks and 21 weeks 5. Competence to look after someone with dementia will be assessed using the Sense of Competence in Dementia Care Staff (SCIDS) scale at baseline, 11 weeks and 21 weeks 6. Carer anxiety and depression is measured using the Hospital Anxiety and Depression Scale (HADS) at baseline, 11 weeks and 21 weeks Previous secondary outcome measures: 1. Participants cognitive functioning is measured using the Modified Memory for Objects test from the Neuropsychological Assessment of Dementia in Intellectual Disabilities Battery at baseline, 11 weeks and 21 weeks, and the Cognitive Scale for Down Syndrome (CS-DS) at baseline, 11 weeks and 21 weeks. 2. Functional ability is measured using ADCS- Activities of Daily Living Inventory (ADCS-ADL) at baseline, 11 weeks and 21 weeks 3. Participant’s health related quality of life is measured using the DEMQOL-proxy at baseline, 11 weeks and 21 weeks 4. Caregiver burden is measured using the Care Giving Burden Scale at baseline, 11 weeks and 21 weeks 5. Time spent caring for the participant with dementia will be measured using the Care Giver Activity Survey-I	—

Measure

Time frame

Current secondary outcome measures as of 03/08/2018: 1. Participants cognitive functioning is measured using the Modified Memory for Objects test from the Neuropsychological Assessment of Dementia in Intellectual Disabilities Battery at baseline, 11 weeks and 21 weeks, and the Cognitive Scale for Down Syndrome (CS-DS) at baseline, 11 weeks and 21 weeks. 2. Functional ability is measured using ADCS- Activities of Daily Living Inventory (ADCS-ADL) at baseline, 11 weeks and 21 weeks 3. Participant’s health related quality of life is measured using the QOL-AD proxy at baseline, 11 weeks and 21 weeks 4. Caregiver burden is measured using the Care Giving Burden Scale at baseline, 11 weeks and 21 weeks 5. Competence to look after someone with dementia will be assessed using the Sense of Competence in Dementia Care Staff (SCIDS) scale at baseline, 11 weeks and 21 weeks 6. Carer anxiety and depression is measured using the Hospital Anxiety and Depression Scale (HADS) at baseline, 11 weeks and 21 weeks Previous secondary outcome measures: 1. Participants cognitive functioning is measured using the Modified Memory for Objects test from the Neuropsychological Assessment of Dementia in Intellectual Disabilities Battery at baseline, 11 weeks and 21 weeks, and the Cognitive Scale for Down Syndrome (CS-DS) at baseline, 11 weeks and 21 weeks. 2. Functional ability is measured using ADCS- Activities of Daily Living Inventory (ADCS-ADL) at baseline, 11 weeks and 21 weeks 3. Participant’s health related quality of life is measured using the DEMQOL-proxy at baseline, 11 weeks and 21 weeks 4. Caregiver burden is measured using the Care Giving Burden Scale at baseline, 11 weeks and 21 weeks 5. Time spent caring for the participant with dementia will be measured using the Care Giver Activity Survey-I

—

Countries

England, United Kingdom

Contacts

Public ContactAfia Ali

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 22, 2026